Mineralys emerges with a new take on an old idea for the treatment of hypertension and $40M to play with

Aldosterone, a hormone linked to increased blood pressure, has long been a target of interest for the treatment of hypertension, but selectivity has been a challenge. Now a new company has emerged from stealth to improve where others have failed.